Page 10 - Bio Media Contact News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme

/PRNewswire/ Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated.

New yorkUnited statesSan franciscoLeo vartorellaNuvation bioNuvation bio incDrug administrationMedivation incFast trackOrphan drug designationDavid hungQuarterly reportBio investor contactBio media contact

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer

/PRNewswire/ Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated.

New yorkUnited statesSan franciscoLeo vartorellaNuvation bioNuvation bio incDrug administrationMedivation incDavid hungQuarterly reportBio investor contactBio media contactHealth care amp hospitalsMedical pharmaceuticalsFda approval

BridgeBio Pharma, Inc ; Helsinn Group: BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types

BridgeBio Pharma, Inc ; Helsinn Group: BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesHong kongPaola bonviciniRiccardo bragliaKatherine yauFrank mccormickHelsinn therapeutics us incDrug administrationExchange commissionGroup head of communicationBridgebio pharma incHelsinn group media contactBio pharma incSecurities exchangeHealth canadaHelsinn group

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease

/PRNewswire/ BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced.

United statesUniversity of massachusetts medical schoolAdam shaywitzFlorian eichlerDominicj gesslerGuangping gaoKatherine yauEric davidBridgebio pharma incLi weibo institute for rare diseases researchEuropean unionDrug administrationLeukodystrophy serviceExchange commissionEuropean medicines agencySecurities exchange

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease - read this article along with other careers information, tips and advice on BioSpace

United statesUniversity of massachusetts medical schoolAdam shaywitzFlorian eichlerDominicj gesslerGuangping gaoKatherine yauEric davidBridgebio pharma incLi weibo institute for rare diseases researchEuropean unionDrug administrationLeukodystrophy serviceExchange commissionEuropean medicines agencySecurities exchange